和黄医药 以上内容基于公开资料整理，不构成投资建议。 分时图 日K线 周K线 月K线 23.26 0.08 0.35% 1.38% 0.91% 0.47% 0.00% 0.47% 0.91% 1.38% 22.86 22.97 23.07 23.18 23.29 23.39 23.50 09:30 10:30 12:00/13:00 14:00 16:10 0 5万 9万 14万 经济观察网和黄医药近期在业务进展与全球合规方面取得多项里程碑。公司计划于2026年3月5日举行董 事会会议审议2025年年度业绩；新型脾酪氨酸激酶抑制剂索乐匹尼布用于治疗温抗体型自身免疫性溶血 性贫血的III期研究已达到主要终点，计划在2026年上半年向中国国家药监局提交新药上市申请；抗体靶 向偶联药物候选药物HMPL-A580和HMPL-A830预计2026年启动1期临床研究；此外，凡瑞格拉替尼和 赛沃替尼的新药申请已获受理并纳入优先审评。另据浦东发布消息，和黄医药上海旗舰生产基地近日 以"零483缺陷项"通过美国食品药品管理局现场检查，进一步夯实全球供应链能力。 近7天(2026年2月7日至13日)和黄医药港股(00013)股价 ...

经济观察网 和黄医药（00013）2026年将有多项关键事件，包括年度业绩发布及重要新药研发进展。 产品研发进展 根据机构研报，公司抗体靶向偶联药物平台中的候选药物HMPL-A580和HMPL-A830预计将在2026年启 动1期临床研究。此外，公司近期管线进展还包括凡瑞格拉替尼和赛沃替尼的新药申请获受理并纳入优 先审评。 业绩经营情况 以上内容基于公开资料整理，不构成投资建议。 公司计划于2026年3月5日举行董事会会议，审议并批准截至2025年12月31日止年度的年度业绩。 业务进展情况 新型脾酪氨酸激酶抑制剂索乐匹尼布用于治疗温抗体型自身免疫性溶血性贫血的III期研究已达到主要终 点，公司计划在2026年上半年向中国国家药监局提交新药上市申请。 ...

Group 1: Key Insights - The report highlights multiple positive catalysts for the electronics sector, particularly for Huadian Co., Ltd. (002463), including the upcoming financial disclosures from overseas cloud vendors and domestic supply chain performance forecasts, which will validate the sustainability of computing power demand and industry prosperity [4] - The defense and military industry, represented by Guoke Military Industry (688543), is transitioning from conventional ammunition to intelligent and information-based ammunition, positioning the company to benefit from high industry demand and military trade orders, which are expected to drive significant growth [4] - In the pharmaceutical and biotechnology sector, Huan Huang Pharmaceutical (0013.HK) is advancing its ATTC platform with candidates entering clinical trials, including HMPL-A251, which is a first-in-class drug, and is also expanding the indications for existing drugs, indicating strong future growth potential [5] Group 2: Company-Specific Analysis - Wan Hua Chemical (600309) is reinforcing its position as a global leader in polyurethane, with significant market shares in MDI and TDI, and is expected to enhance profitability through strategic partnerships and cost advantages in its petrochemical segment [6] - Su Kan Agricultural Development (601952) anticipates a slight decline in 2025 profits due to falling grain prices, but expects a recovery driven by rising grain prices and increased farmland area through land transfer initiatives [7] - Yingwei Technology (002837) is poised for substantial growth in the server liquid cooling market, with expectations of doubling industry growth in 2026 and 2027, supported by orders from major overseas clients [8] Group 3: Financial Performance and Projections - China Pacific Insurance (601601) demonstrated strong resilience with a 11% year-on-year increase in net profit to 27.9 billion yuan, driven by robust growth in new business value in its life insurance segment [8] - Jin Jiang Shipping (601083) reported a 64% year-on-year increase in net profit for Q3, indicating strong performance relative to peers, with expectations for continued growth [8] - Xiaoshangcheng (600415) is benefiting from increased rental income and new merchant additions, with projections for profit doubling in 2026 due to enhanced service offerings and improved gross margins [8]

Investment Rating - The report maintains an investment rating of "Outperform" [6] Core Insights - The report highlights the potential of small nucleic acid drugs in weight loss applications, validated by Arrowhead Pharmaceuticals' recent data on INHBE and ALK7 targeted siRNA drugs [3][28] - The new drug sector has shown significant price movements, with notable gains from companies like Frontline Bio (+55.96%) and Shengnuo Pharma (+27.25%) during the week of January 5 to January 11, 2026 [1][16] - There are multiple catalysts expected in the sector, including academic conferences and data releases, which could drive further interest in specific companies [2] Weekly New Drug Market Review - From January 5 to January 11, 2026, the top five gainers in the new drug sector were Frontline Bio (+55.96%), Shengnuo Pharma (+27.25%), Rongchang Bio (+24.64%), Yifang Bio (+22.61%), and Zhixiang Jintai (+19.09%) [1][16] - The top five decliners included Jiahe Bio (-10.69%), Junsheng Tai (-10.56%), Beihai Kangcheng (-5.51%), Yongtai Bio (-3.15%), and Laikai Pharma (-1.84%) [1][16] Weekly Focus on Recommended Stocks - Companies with high overseas growth potential certified by MNCs include Sanofi Pharma, Lianbang Pharma, and Kelun Biotech [2] - Companies with overseas data catalysts include Betta Pharma, Hutchison China MediTech, and Yingen Bio [2] - Potential heavyweights for overseas licensing include Fuhong Hanlin, CSPC Pharmaceutical Group, and Yifang Bio [2] - New innovative drug technology breakthroughs are expected in areas such as small nucleic acids, in vivo CAR-T, fat loss and muscle gain, autoimmune CAR-T/bispecific antibodies, and gene therapy [2] New Drug Industry Key Analysis - Arrowhead Pharmaceuticals has disclosed early weight loss data for its INHBE-targeted siRNA drug, further validating the application potential of small nucleic acid drugs in weight loss [3][28] - Domestic companies are actively developing INHBE-targeted siRNA drugs, including major players like Dairui Bio, Shengyin Bio, and Bowe Pharmaceutical [3][34] - The ALK7-targeted siRNA drug ARO-ALK7 has shown promising results, with a significant reduction in visceral fat observed in clinical trials [40][41] New Drug Approval and Acceptance Status - This week, 8 new drug or new indication applications were approved in China, while 20 applications were accepted [4][43] - The approved drugs include various formulations and indications, such as the injection of human thyroid-stimulating hormone beta and the injection of relaflufin alpha [44] New Drug Clinical Application Approval and Acceptance Status - A total of 47 new drug clinical applications were approved this week, with 46 applications accepted [10][48]

Core Viewpoint - In 2025, despite a significant market downturn, the Hang Seng Healthcare Index maintained an annual increase of over 50%, while Hutchison China MediTech (00013) experienced an annual decline of 8.56%, underperforming the index significantly [1] Group 1: Stock Performance - Hutchison China MediTech's stock reached a peak increase of only 36.36% in 2025, with a notable decline in the second half of the year, where the stock price fell from a high of HKD 30.75 to a low of HKD 19.95, marking a maximum drop of 35.12% over four and a half months [1] - The stock showed a rebound at the beginning of 2026, achieving a "five consecutive days of gains" with a peak single-day trading volume of 15.45 million shares, the highest since October of the previous year [1] Group 2: Financial Performance - In the 2025 mid-year report, the company reported revenues of USD 278 million, a year-on-year decrease of 9.2%. However, due to the sale of non-core joint venture equity, net profit surged to USD 455 million, a 16.6-fold increase [2] - The sales of the company's three main innovative drugs, including Fuzulopatinib, Surufatinib, and Savolitinib, saw a significant decline of 30-50%, leading to a 22% year-on-year drop in self-owned product sales [2] Group 3: Market Sentiment and Trading Behavior - Following the mid-year report, the stock price underwent a month-long adjustment, with a brief recovery in mid-September, but this was interrupted by a decline in the Hang Seng Healthcare Index [3] - The stock exhibited a "follow the market down" behavior, with a shift in trading style among investors, particularly in the Hong Kong Stock Connect, which began to align more closely with the stock's price movements starting in November [5] Group 4: Pipeline and Future Prospects - The decline in stock performance in 2025 was attributed to the lack of commercial performance from the main innovative drugs, creating a gap in the second half of the year [7] - The company has developed a diversified pipeline from oncology to autoimmune diseases, with several candidates entering critical clinical stages, including Sovleplenib, HMPL-453, HMPL-306, and HMPL-506 [7] - Recent updates on the progress of new and existing pipeline products have driven the stock's rebound, with significant announcements regarding new drug applications and clinical trial advancements [8][9] Group 5: Specific Drug Developments - Sovleplenib, a selective oral SYK inhibitor, is expected to be approved this year for the treatment of refractory/relapsed primary immune thrombocytopenia (ITP), potentially generating new revenue streams [9] - HMPL-453, a selective and potent FGFR1/2/3 inhibitor, is anticipated to be approved by 2027, indicating a long-term growth potential for the company [10]

Group 1: Overseas Service Industry - The investment rating for the overseas service industry is positive, with Macau's gaming revenue maintaining double-digit growth and visitor numbers reaching historical highs [1][3]. - In December, Macau's gross gaming revenue was 20.9 billion MOP, representing a year-on-year increase of 14.8%, and recovering to 91% compared to the same period in 2019 [3]. - The total number of visitors to Macau in 2025 is projected to be 40.06 million, a year-on-year increase of 14.7%, marking a historical high [3]. Group 2: Overseas Pharmaceutical Industry - The investment rating for the overseas pharmaceutical industry is optimistic, with significant advancements in drug approvals and clinical trials [2][6]. - BeiGene's BCL2 inhibitor received conditional approval in China for treating chronic lymphocytic leukemia and mantle cell lymphoma, marking it as the first approved BCL2 inhibitor for MCL in the country [6][7]. - The Hang Seng Healthcare Index rose by 11.15%, outperforming the Hang Seng Index by 9.12 percentage points [6]. Group 3: Overseas Education Industry - The investment rating for the overseas education industry is favorable, with a focus on vocational training and spring enrollment [12][14]. - The education index increased by 2.7% in the first week of January, outperforming the Hang Seng National Enterprises Index by 1.3 percentage points [12]. - China Oriental Education is recommended as a top pick due to its proactive operational adjustments and expected enrollment growth in the second half of the year [14].

Group 1: Overseas Social Services - The investment rating for the overseas social services sector is positive, with a focus on Macau's gaming revenue maintaining double-digit growth and record visitor numbers during New Year's [1][4]. - In December, Macau's gross gaming revenue reached 20.9 billion MOP, representing a year-on-year increase of 14.8%, and recovering to 91% compared to the same period in 2019. The total gross gaming revenue is expected to grow by 9.1% in 2025 [4]. - The total number of visitors to Macau in 2025 is projected to be 40.06 million, a year-on-year increase of 14.7%, marking a historical high. On New Year's Day 2026, the number of visitors reached 188,000, the highest ever for that day [4]. Group 2: Overseas Pharmaceuticals - The investment rating for the overseas pharmaceuticals sector is also positive, with significant developments in drug approvals and clinical trials [2][7]. - BeiGene's BCL2 inhibitor received conditional approval in China for treating chronic lymphocytic leukemia and mantle cell lymphoma, marking it as the first and only BCL2 inhibitor approved for MCL in the country [8][9]. - The Hang Seng Healthcare Index rose by 11.15%, outperforming the Hang Seng Index by 9.12 percentage points, indicating strong market performance [7]. Group 3: Overseas Education - The investment rating for the overseas education sector is favorable, with a focus on vocational education and training [3][14]. - The education index increased by 2.7%, outperforming the Hang Seng Index by 1.3 percentage points, indicating a positive market trend [14]. - The report suggests focusing on Hong Kong vocational education companies, particularly China Oriental Education, which is expected to see enrollment growth due to strategic adjustments in response to market demand [16].

Group 1 - Kangfang Biotech (09926) shares rose over 6% after the approval of an important update to the product label for its PD-1/VEGF bispecific antibody, Ivosidenib, which showed significant clinical benefits in treating advanced non-squamous non-small cell lung cancer [1] - Sunac China (01918) shares fell over 6% as the company reported a contract sales amount of 2.95 billion RMB in December, a year-on-year increase of 68.6%, but with a decrease in average sales price per square meter by 14.4% [1] - Nanshan Aluminum International (02610) saw a nearly 14% increase in shares, attributed to a tight global electrolytic aluminum market, with Indonesia being a key marginal supplier [1] Group 2 - Optical communication stocks rebounded, with Longi Fiber Optic (06869) up 7.46% and Cambridge Technology (06166) up 3.86%, following a significant rise in U.S. optical communication stocks [2] - Hengrui Medicine (01276) shares increased over 2.8% after announcing the approval of two innovative drugs for clinical trials targeting prostate cancer [2] - Cao Cao Travel (02643) shares rose over 7% following the announcement of acquisitions of Yao Travel and Geely Business Travel [2] Group 3 - Hutchison China MediTech (00013) shares increased over 5.3% after announcing positive results from a Phase III trial for a new treatment for autoimmune hemolytic anemia [3] - Geekplus Technology (02590) shares rose slightly by 0.51%, with a report highlighting its stable business model and growth potential due to AI applications [3] Group 4 - Xuan Bamboo Biotech (02575) shares surged over 11.6% after its drug, Pyrotinib, was included in the national medical insurance directory, providing new benefits for advanced breast cancer patients [4] Group 5 - Semiconductor equipment and materials stocks continued to rise, with significant gains for companies like Amkor Technology (AMKR.US) and Lam Research (LRCX.US) [5] - Chinese concept stocks mostly rose, with notable increases for Hesai (HSAI.US) and Pinduoduo (PDD.US), amid a bullish market sentiment [5] - Uber (UBER.US) and Lyft (LYFT.US) saw stock price increases following Nvidia's announcement of advancements in autonomous driving technology [5] Group 6 - Data center cooling stocks experienced a decline, with companies like Modine Manufacturing (MOD.US) and Johnson Controls (JCI.US) facing significant drops [6] - Copper stocks strengthened, with Freeport-McMoRan (FCX.US) and Southern Copper (SCCO.US) showing notable gains as copper futures reached a historic high [6] - The storage sector continued its upward trend, with SanDisk (SNDK.US) achieving a 27.56% increase after launching a new SSD product line [6] Group 7 - Alumis (ALMS.US) shares skyrocketed by 95.31% following positive results from clinical trials for its TYK2 inhibitor targeting psoriasis patients [7] - Tesla (TSLA.US) shares fell over 4.14% as BYD surpassed Tesla in electric vehicle sales in key European markets [7] - Zeta Global (ZETA.US) shares rose 9.83% after announcing a strategic partnership with OpenAI to enhance its product capabilities [7]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 3%, currently up 3.1% at HKD 21.98, with a trading volume of HKD 44.32 million [1] Group 1: Clinical Research - On January 7, Hutchison China MediTech announced that its Syk inhibitor, Sola-pinib, has met the primary endpoint of durable hemoglobin (Hb) response during the 5 to 24 weeks treatment period in the ESLIM-02 study for adult patients with warm antibody autoimmune hemolytic anemia [1] - The ESLIM-02 study is a randomized, double-blind, placebo-controlled clinical trial conducted in China for adult patients with relapsed or refractory primary or secondary warm antibody autoimmune hemolytic anemia who have received at least one standard treatment [1] - The results of the Phase II portion of the ESLIM-02 study were published in The Lancet Haematology in January 2025 [1] Group 2: Future Plans - Hutchison China MediTech plans to submit a new drug application for Sola-pinib to the National Medical Products Administration of China in the first half of 2026 for the treatment of warm antibody autoimmune hemolytic anemia [1] - Complete data from the ESLIM-02 study will be presented at an upcoming academic conference [1]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) has seen a stock increase of over 3%, currently trading at HKD 21.98, following the announcement of positive results from the ESLIM-02 study for its Syk inhibitor, selinexor, in treating warm antibody autoimmune hemolytic anemia in adults [1]. Group 1: Study Announcement - On January 7, Hutchison China MediTech announced that the ESLIM-02 study, a Phase III registration trial, has met its primary endpoint of durable hemoglobin response during the treatment period from week 5 to week 24 [1]. - The ESLIM-02 study is a randomized, double-blind, placebo-controlled clinical trial conducted in China, targeting adult patients with relapsed or refractory warm antibody autoimmune hemolytic anemia who have previously received at least one standard treatment [1]. - Results from the Phase II portion of the ESLIM-02 study were published in The Lancet Haematology in January 2025 [1]. Group 2: Future Plans - Hutchison China MediTech plans to submit a new drug application for selinexor to the National Medical Products Administration of China in the first half of 2026 for the treatment of warm antibody autoimmune hemolytic anemia [1]. - Complete data from the ESLIM-02 study will be presented at an upcoming academic conference [1].